The current findings indicate that PD-L1 and CD4+ helper T cells may be reasonable targets for improving survival via enhancing chemosensitivity, providing useful information for combining immunotherapies into the therapeutic strategy for endometrial carcinoma. This evidence concerns the gene CD274 and endometrial carcinoma.